NASDAQ:THAR Tharimmune (THAR) Stock Price, News & Analysis $2.38 -0.01 (-0.21%) As of 09/30/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Tharimmune Stock (NASDAQ:THAR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tharimmune alerts:Sign Up Key Stats Today's Range$2.37▼$2.4950-Day Range$1.85▼$2.6952-Week Range$0.95▼$9.08Volume446,132 shsAverage Volume1.48 million shsMarket Capitalization$89.61 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Tharimmune, Inc. is a clinical-stage biotechnology company focused on developing therapies for immune-mediated and inflammatory diseases. The company’s research and development programs are aimed at conditions with significant unmet medical needs, including disorders associated with chronic itching and inflammation. Tharimmune’s lead candidate is TH104, a buccal film formulation of aprepitant being developed for the treatment of chronic pruritus associated with cholestatic liver disease. The company is also advancing additional preclinical and clinical-stage programs intended to address immune and inflammatory conditions. Tharimmune does not currently have a marketed product, and its candidates remain subject to clinical, regulatory, and commercial development risks. The company is based in the United States and is developing its pipeline for potential use in broader international markets. Its shares trade on the Nasdaq Capital Market under the symbol THAR.AI Generated. May Contain Errors. Read More Tharimmune Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks0th Percentile Overall ScoreTHAR MarketRank™: Tharimmune scored higher than 0% of companies evaluated by MarketBeat, and ranked 855th out of 855 stocks in the finance sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingTharimmune has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageTharimmune has received no research coverage in the past 90 days.Read more about Tharimmune's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Tharimmune is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tharimmune is -0.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTharimmune has a P/B Ratio of 3.49. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for THAR. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTharimmune does not currently pay a dividend.Dividend GrowthTharimmune does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Tharimmune this week, compared to 1 article on an average week. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Tharimmune insiders have not sold or bought any company stock.Percentage Held by Insiders6.70% of the stock of Tharimmune is held by insiders.Percentage Held by Institutions1.16% of the stock of Tharimmune is held by institutions.Read more about Tharimmune's insider trading history. Receive THAR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tharimmune and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. THAR Stock News HeadlinesTharimmune (NASDAQ:THAR) Stock Jumps 3.1% - Time to Buy?September 26, 2026 | americanbankingnews.comTharimmune Inc.May 13, 2026 | wsj.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.October 1 at 1:00 AM | Banyan Hill Publishing (Ad)Tharimmune Rebrands as Canton Strategic Holdings, Updates TickerFebruary 18, 2026 | tipranks.comTharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury StrategyFebruary 17, 2026 | prnewswire.comCatherine Wood's Strategic Moves: A Closer Look at Tesla Inc's Portfolio ImpactFebruary 11, 2026 | finance.yahoo.comTharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating OfficerFebruary 6, 2026 | prnewswire.comTharimmune Elects Jill Sommers and William Wiley to Board of DirectorsFebruary 2, 2026 | prnewswire.comSee More Headlines THAR Stock Analysis - Frequently Asked Questions How have THAR shares performed this year? Tharimmune's stock was trading at $3.03 at the beginning of 2026. Since then, THAR shares have decreased by 21.6% and is now trading at $2.3750. How were Tharimmune's earnings last quarter? Tharimmune, Inc. (NASDAQ:THAR) released its earnings results on Thursday, August, 14th. The company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by $0.06. When did Tharimmune's stock split? Shares of Tharimmune reverse split on Tuesday, May 28th 2024.The 1-15 reverse split was announced on Tuesday, May 28th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Tharimmune IPO? Tharimmune (THAR) raised $21 million in an IPO on the week of January 10th 2022. The company issued 3,750,000 shares at a price of $5.00-$6.00 per share. How do I buy shares of Tharimmune? Shares of THAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tharimmune own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tharimmune investors own include Jiuzi (JZXN), Avenue Therapeutics (ATXI), Scinai Immunotherapeutics (SCNI), Adial Pharmaceuticals (ADIL), Sphere 3D (ANY), Company Calendar Last Earnings8/14/2025Today10/01/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorFinance Industry Financial Services Sub-IndustryMulti-Sector Holdings Current SymbolNASDAQ:THAR Previous SymbolNASDAQ:THAR CIK1861657 Webwww.hillstreambio.com Phone908-955-3140FaxN/AEmployees2Year FoundedN/AProfitability EPS (Trailing Twelve Months)($3.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.20 million Net MarginsN/A Pretax MarginN/A Return on Equity-588.45% Return on Assets-264.41% Debt Debt-to-Equity RatioN/A Current Ratio4.98 Quick Ratio4.98 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.68 per share Price / Book3.49Miscellaneous Outstanding Shares37,730,000Free Float35,202,000Market Cap$89.61 million OptionableNot Optionable Beta1.43 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:THAR) was last updated on 10/1/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tharimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tharimmune With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
